ExScientia Ltd

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The firm has designed three drugs that are in phase 1 human clinical trials. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ExScientia reports robust Q4 earnings, poised for precision medicine growth

ExScientia's Q4 2022 earnings call highlighted strong financial performance, key collaborations, and advancements in pipeline programs. The company's focus on AI-driven precision medicine and solid cash position bode well for future growth. Challenges in program management and cost control exist, but opportunities for innovation and partnerships are abundant.

ExScientia reports 15% revenue growth, poised for precision medicine leadership

ExScientia Ltd delivered strong financial performance with a 15% increase in quarterly revenue and a robust cash position, driven by successful product launches and cost-saving initiatives.
The company's focus on personalized medicine, innovative product development, and strategic financial management positions it well for future growth and market leadership.
While facing challenges in molecule differentiation and cost efficiency, ExScientia has opportunities to leverage biomarkers, advance clinical programs, and expand market presence.

ExScientia advances clinical trials and precision medicine with strong financials

ExScientia's Q2 2023 earnings call showcased progress in clinical trials, precision medicine, and AI integration, supported by a strong financial position.
The company's focus on innovation, cost efficiency, and strategic partnerships positions them well for future growth and advancements in drug discovery.
Challenges lie in managing milestone payments, operational complexities, and staying competitive through biologics investments and partnerships.
Opportunities abound in expanding collaborations, attracting industry interest, and unveiling advancements in biologics for pipeline growth from 2024 onwards.

ExScientia excels in Q3, poised for growth in precision medicine

ExScientia's Q3 performance reflects progress in oncology programs, financial strength, and a focus on precision drug design and partnerships.
The company's strengths lie in its robust cash position, innovative approach to drug design, and operational efficiency influenced by past projects.
Challenges include market adaptability, program prioritization, and maintaining competitiveness, while opportunities exist in advancing the pipeline and leveraging partnerships for growth.

ExScientia reports robust Q4 earnings, eyes growth through innovation

ExScientia's Q4 2023 earnings call showcases strong financial and operational performance.
The company's focus on innovation, partnerships, and efficiency drives growth.
Challenges include competition, innovation sustainability, and quality maintenance.
Opportunities lie in business development, automation, and efficient drug creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

Exact Sciences

vTv Therapeutics

Healthcare stocks have started the year off very strongly, propelled by excitement about weight loss drugs and investments by Nvidia (NASDAQ: NVDA ). The sector is also getting a lift from the U.S. Federal Reserve's decision to stop raising rates and its suggestions that it will cut rates later this year.

The Top 3 Healthcare Stocks to Buy on Weakness in 2024

NEW YORK, NY / ACCESSWIRE / March 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Exscientia plc ("Exscientia plc") (NASDAQ:EXAI) concerning possible violations of federal securities laws. Exscientia issued a press release, on February 13, 2024, "announc[ing] that its Board of Directors (the ‘Board') has decided to terminate the employment of Andrew Hopkins as the Company's Chief Executive Officer and Principal Executive Officer, and to remove Dr. Hopkins from his role as an Executive Director of the Board, in each case for cause and effective immediately.

Exscientia plc (EXAI) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

NEW YORK, NY / ACCESSWIRE / March 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Exscientia plc ("Exscientia plc") (NASDAQ:EXAI) concerning possible violations of federal securities laws. Exscientia issued a press release, on February 13, 2024, "announc[ing] that its Board of Directors (the ‘Board') has decided to terminate the employment of Andrew Hopkins as the Company's Chief Executive Officer and Principal Executive Officer, and to remove Dr. Hopkins from his role as an Executive Director of the Board, in each case for cause and effective immediately.

Did Exscientia plc Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - EXAI

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March: TD Cowen 44th Annual Health Care Conference. Fireside chat on Wednesday, March 6, 2024 at 2:10 p.m. EST (7:10 p.m. GMT) in Boston, Massachusetts Barclays 26th Annual Global Healthcare Conference. Fireside chat on Tuesday, March 12, 2024 at 1:05 p.m. EDT (5:05 p.m. GMT) in Miami, Florida KeyBanc Capital Markets Life S.

Exscientia to Present at Upcoming Investor Conferences in March

NEW YORK--(BUSINESS WIRE)---- $EXAI #classaction--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Exscientia plc (“Exscientia” or “the Company”) (NASDAQ: EXAI). Investors who purchased Exscientia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/EXAI. Investigation Details: On February 13, 2024, Exscientia issued a press release “announc[ing] that its Board of Directors (the ‘Board') has d.

Exscientia plc (EXAI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Nasdaq-listed Exscientia shares crashed by more than a fifth as the Oxford-based biotech fired its founder and chief executive over "inappropriate relationships" with two employees. In a statement, the AI-focused drug developer said that Andrew Hopkins's behaviour was inconsistent with “the company's standards and values”.

Exscientia boss departs over relationships with employees

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-2, an observational clinical study in acute myeloid leukaemia (AML) to investigate the relationship between ex vivo drug response (EVDR) measured in primary blood or bone marrow samples using the company's deep learning, single-cell precision medicine platform and actual patient clinical response. The EXCYTE-2 study will collect blood and bone marrow samples from first-line patients with AML.

Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients

Dominion Energy

Datadog

Easterly Government Properties

Duolingo

e.l.f. Beauty

Eversource Energy

Encore Energy Corp

This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income.

MoneyShow's Best Investment Ideas For 2024: Part 4

GlaxoSmithKline

Pfizer

Integrating artificial intelligence and biotechnology could make 2024 a landmark year. The utilization of AI, machine learning and big data is nowadays a part of research and development (R&D) procedures in most pharmaceutical companies, positioning them well to expedite the approval of new drugs for the market.

The Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech Breakthroughs

ImmunityBio

Viking Therapeutics

Two factors –lower interest rates and the low valuation of many biotech stocks — are likely to result in many biotech companies being acquired in 2024. Lower interest rates will result in many drug maker stocks being acquired because cheaper borrowing costs will make it cheaper for firms to borrow the money that they need to finance deals.

M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024

OXFORD, England--(BUSINESS WIRE)--Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been appointed Commander of the Order of the British Empire (CBE) for services to Science and Innovation by His Majesty King Charles III. The distinguished honour comes as part of HM The King's 2024 New Year Honours List, recognising the achievements and service of extraordinary people across the UK who have been recommended by the Prime Minister based on an.

Professor Andrew L. Hopkins appointed Commander of the Order of the British Empire (CBE)

The consensus price target hints at a 67.8% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 67.76% Upside in Exscientia PLC Sponsored ADR (EXAI): Can the Stock Really Move This High?

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that Sanofi is adding a new discovery stage programme identified and initially advanced by Exscientia into the current collaboration. In this programme, Exscientia has designed a novel lead series with a potential best in class profile, with preliminary data showing good potency and selectivity towards the target and differentiated molecular properties. “Sanofi adding an Exscientia discovery stage programme into the.

Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme

Exscientia is a pharmaceutical company using AI-based precision engineering to revolutionize drug discovery and reduce drug creation by 70%. The company has strong financials, with a cash runway into 2026 and partnerships with industry giants such as Sanofi and Merck KGaA. Exscientia's AI-driven precision platform has promising applications in oncology and other medical areas, with a focus on personalized and effective treatments.

Exscientia Looks Promising In AI-Driven Drug Development

Exscientia hopes its AI tools will make it easier to discover new medicines. A few big pharma companies seem to think that it's on to something.

Looking for the Next Big Thing? Add This AI Biotech to Your Watch List Right Now

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) announced today that the Company received a $2.3 million grant from Open Philanthropy, a philanthropic funder with several programs in global health and wellbeing. Under this grant, Exscientia aims to harness the activation of the host interferon response as a therapeutic approach for pandemic influenza. The grant comes in the context of the wider Pandemic Antiviral Discovery (PAD) initiative. Out of the COVID-19 pandemic experienc.

Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza

The mean of analysts' price targets for Exscientia PLC Sponsored ADR (EXAI) points to a 68% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 68.03%: Read This Before Placing a Bet

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 3:25 p.m. EST (8:25 p.m. GMT). A live webcast of the fireside chat will be available on the Company's website, under the “Investors & Media” section at investors.exscientia.ai. An archived replay of the webcast will be available for approximately 30 days.

Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference

The consensus price target hints at a 76.1% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Exscientia PLC Sponsored ADR (EXAI) Could Rally 76.12%: Here's is How to Trade

Ginkgo Bioworks Holdings

Schrodinger 

Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks. Fundamentally, the reasoning centers on relative insulation.

3 Cutting-Edge Biotech Stocks for the Bold Investor

Exscientia plc (NASDAQ:EXAI ) Q3 2023 Results Conference Call November 9, 2023 8:30 AM ET Company Participants Sara Sherman - VP, IR Andrew Hopkins - CEO Dave Hallett - Chief Scientific Officer Ben Taylor - CFO and Chief Strategy Officer Dr. Mike Krams - Chief Quantitative Medicine Officer Conference Call Participants Alec Stranahan - Bank of America Peter Lawson - Barclays Chris Shibutani - Goldman Sachs Operator Hello, everyone. My name is Sarah, and I will be your conference operator today.

Exscientia plc (EXAI) Q3 2023 Earnings Call Transcript

OXFORD, U.K.--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below. Exscientia will host a conference call Thursday, November 9 at 1:30 p.m. GMT / 8:30 a.m. EST. “At Exscientia, we are laser-focused on building an engine that designs and develops high impact medicines that have the potential to transform patients' lives,” said Professor Andrew.

Exscientia Business Update for Third Quarter 2023

Exscientia (EXAI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Exscientia (EXAI) This Earnings Season?

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. EST to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company's website at investors.exscientia.ai. Alterna.

Exscientia to Report Third Quarter 2023 Financial Results on November 9, 2023

The mean of analysts' price targets for Exscientia PLC Sponsored ADR (EXAI) points to a 104.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

News for ExScientia Ltd Stock (EXAI)